Abstract
The 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibitors (statins) are a class of drug used to lower low-density lipoprotein (LDL) levels. However, in recent years, statins have been shown to possess a pleiotropic effect beyond its cholesterol lowering ability, including attenuating the effect of ischaemia reperfusion injury. This review considers the biomolecular processes that may lead to this beneficial effect.
Keywords: Ischaemia reperfusion injury, statins, 3-hydroxy-3-methyl-glutaryl-CoA, reductase inhibitors, low-density lipoprotein, inflammatory re-sponse syndrome, multi organs dysfunction syn-drome, tissue hypoxia, hypoxanthine, xanthine oxidase, reactive oxygen species, nuclear factor B, activator protein-1, nitric oxide, endothelial dysfunction, inter-leukin (IL)-1, tumour necrosis factor alpha, platelet-activating factor, sialyl Lewis X, thrombin, cytokines, vascular endothelial cadherin, angioplasty, cholesterol biosynthesis, lovastatin, pravastatin, simvastatin, atorvastatin, cerivastatin, fluvastatin, rosuvastatin, cytochrome P450, coronary heart disease, rhabdo-myolysis, endothelial NO synthase, inducible NO synthase, neuronal NO synthase, Pro-Inflammatory Cytokines, PAF receptor, endothelin-1, monocyte chemoattractant protein-1, thrombomodulin, cytokine transcription, C-reactive protein, Leukocytes-Endothelial Interaction, decay-accelerating factor, protein kinase C, NADPH-oxidase, ROS reduction
Current Vascular Pharmacology
Title: Statins and Ischaemia Reperfusion Injury: A Molecular Biological Review
Volume: 8 Issue: 6
Author(s): M. N.A. Abdul Rahman and Ian C. Chetter
Affiliation:
Keywords: Ischaemia reperfusion injury, statins, 3-hydroxy-3-methyl-glutaryl-CoA, reductase inhibitors, low-density lipoprotein, inflammatory re-sponse syndrome, multi organs dysfunction syn-drome, tissue hypoxia, hypoxanthine, xanthine oxidase, reactive oxygen species, nuclear factor B, activator protein-1, nitric oxide, endothelial dysfunction, inter-leukin (IL)-1, tumour necrosis factor alpha, platelet-activating factor, sialyl Lewis X, thrombin, cytokines, vascular endothelial cadherin, angioplasty, cholesterol biosynthesis, lovastatin, pravastatin, simvastatin, atorvastatin, cerivastatin, fluvastatin, rosuvastatin, cytochrome P450, coronary heart disease, rhabdo-myolysis, endothelial NO synthase, inducible NO synthase, neuronal NO synthase, Pro-Inflammatory Cytokines, PAF receptor, endothelin-1, monocyte chemoattractant protein-1, thrombomodulin, cytokine transcription, C-reactive protein, Leukocytes-Endothelial Interaction, decay-accelerating factor, protein kinase C, NADPH-oxidase, ROS reduction
Abstract: The 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibitors (statins) are a class of drug used to lower low-density lipoprotein (LDL) levels. However, in recent years, statins have been shown to possess a pleiotropic effect beyond its cholesterol lowering ability, including attenuating the effect of ischaemia reperfusion injury. This review considers the biomolecular processes that may lead to this beneficial effect.
Export Options
About this article
Cite this article as:
N.A. Abdul Rahman M. and C. Chetter Ian, Statins and Ischaemia Reperfusion Injury: A Molecular Biological Review, Current Vascular Pharmacology 2010; 8 (6) . https://dx.doi.org/10.2174/157016110793563780
DOI https://dx.doi.org/10.2174/157016110793563780 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Sesamin and Sesamolin: Natures Therapeutic Lignans
Current Enzyme Inhibition Dysfunctions of the Diffusional Membrane Pathways Mediated Hemichannels in Inherited and Acquired Human Diseases
Current Vascular Pharmacology In Silico Identification of Novel Orthosteric Inhibitors of Sphingosine Kinase 1 (SK1)
Current Protein & Peptide Science Surgical or Interventional Revascularization in Diabetic Patients with Coronary Artery Disease?
Current Diabetes Reviews Connection between JAK/STAT and PPARγ Signaling During the Progression of Multiple Sclerosis: Insights into the Modulation of T-Cells and Immune Responses in the Brain
Current Molecular Pharmacology Pharmacological Characteristics and Clinical Applications of K201
Current Clinical Pharmacology Meet the Editorial Board
Current Drug Targets Vagal Stimulation Facilitates Improving Effects of Ranolazine on Cardiac Function in Rats with Chronic Ischemic Heart Failure
Current Molecular Medicine Studies on the Biotransformations and Biodistributions of Metal-Containing Drugs Using X-Ray Absorption Spectroscopy
Current Topics in Medicinal Chemistry Flavonoids and the Brain: Evidences and Putative Mechanisms for a Protective Capacity
Current Neuropharmacology Metabolic Imbalance of Homocysteine and Hydrogen Sulfide in Kidney Disease
Current Medicinal Chemistry Review on Patents for Ubiquitin-Proteasome Inhibitor as Medical Advance in Major Human Diseases
Recent Patents on Biomedical Engineering (Discontinued) Soluble Forms of RAGE in Human Diseases: Clinical and Therapeutical Implications
Current Medicinal Chemistry OPA1 in Cardiovascular Health and Disease
Current Drug Targets Cardioprotection Techniques: Preconditioning, Postconditioning and Remote Con-ditioning (Basic Science)
Current Pharmaceutical Design Editorial (Thematic Issue: Modifying Cardiovascular Risk Factors: Current Opinion and Future Trends)
Current Pharmaceutical Design The Development of Preventives and Therapeutics for Alzheimers Disease that Inhibit the Formation of β-Amyloid Fibrils (fAβ), as Well as Destabilize Preformed fAβ
Current Pharmaceutical Design COX-2 in Brain and Spinal Cord - Implications for Therapeutic Use.
Current Medicinal Chemistry Mechanisms Involved in Neuroprotective Effects of Transcranial Magnetic Stimulation
CNS & Neurological Disorders - Drug Targets Diallyl Sulfide: Potential Use in Novel Therapeutic Interventions in Alcohol, Drugs, and Disease Mediated Cellular Toxicity by Targeting Cytochrome P450 2E1
Current Drug Metabolism